Buy This Dividend King for 2022 and Beyond
Hitting consistent singles and doubles in investing with well-established companies is arguably the secret to successful investing. Sure, it's more exciting to hit a home run with less established businesses. But that also often carries significantly more risk.
Founded in 1886, Johnson & Johnson (NYSE: JNJ) is one of the oldest pharmaceutical companies in the world. As a well-established business, J&J has been able to raise its dividend for 60 consecutive years. This makes the company a Dividend King with the longest dividend growth streak in all of healthcare.
But don't mistake J&J's age and impressive dividend growth streak as a sign of a stagnant business whose best days are behind it. The stock appears to be a buy for value- and income-oriented investors this year and well beyond. Let's dive into J&J's fundamentals and valuation to elaborate on this argument further.
Source Fool.com
